Gianni Binotto

Padova, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 107 publications

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 09, 2026

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Journal: Cancers

Published: April 08, 2026

From variant detection to interpretation in idiopathic erythrocytosis: A structured approach applied to a clinical cohort.

From variant detection to interpretation in idiopathic erythrocytosis: A structured approach applied to a clinical cohort.

Journal: British journal of haematology

Published: March 24, 2026

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Journal: Leukemia research

Published: March 06, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

Journal: European journal of haematology

Published: February 24, 2026

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Journal: Cancer

Published: December 16, 2025

Scleredema Associated With IgG/κ Monoclonal Gammopathy of Clinical Significance Successfully Treated With Daratumumab Monotherapy: A Case Report.

Scleredema Associated With IgG/κ Monoclonal Gammopathy of Clinical Significance Successfully Treated With Daratumumab Monotherapy: A Case Report.

Journal: EJHaem

Published: December 05, 2025

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Journal: Cancer

Published: November 16, 2025

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology

Published: November 13, 2025

GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists.

GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists.

Journal: Frontiers in oncology

Published: September 02, 2025

Showing 1-12 of 107

Last Updated: 09/26/2026